A Rare Case of Atypical Haemolytic Syndrome Following Right Retrograde Intrarenal Surgery (RIRS)

Antonio Cretì, Francesco Pinto, Maria Chiara Sighinolfi, Bernardo Rocco, Domenico Salvatore Nigro, Mauro RagoneseCureus 2025 · DOI

TL;DR

This case report documents the first known instance of atypical hemolytic uremic syndrome (aHUS) triggered by a minimally invasive endoscopic urological procedure (Retrograde Intrarenal Surgery). It highlights how surgical stress can act as a "second hit" for complement system dysregulation and demonstrates that prophylactic treatment with eculizumab can successfully prevent recurrence during subsequent high-risk surgeries.

What Problem Does This Paper Address?

The paper addresses the diagnostic and management challenges of a rare, life-threatening condition called atypical hemolytic uremic syndrome (aHUS) when it appears as a postoperative complication.

aHUS is characterized by a triad of acute renal failure, non-immune hemolytic anemia (destruction of red blood cells), and thrombocytopenia (low platelet count). It is driven by an overactive complement system—a part of the immune system that, when dysregulated, attacks the body’s own blood vessels. While typically associated with genetic predispositions or major systemic triggers, this paper explores the "gap" in clinical knowledge regarding aHUS triggered by "low-risk," minimally invasive endoscopic procedures. In a postoperative setting, aHUS can easily be mistaken for standard septic shock, leading to dangerous delays in targeted treatment.

Methods

As a clinical case report, the "methods" describe the multidisciplinary diagnostic and therapeutic pathway used to manage the patient:

  • Differential Diagnosis: To distinguish aHUS from other forms of thrombotic microangiopathy (like TTP), the team performed ADAMTS13 activity testing (which was normal at 75%) and complement assays, which revealed significantly reduced Complement Factor H activity.
  • Acute Management: The patient received a combination of:
  • Continuous Venovenous Hemodiafiltration (CVVHDF): For renal support during acute kidney injury.
  • Therapeutic Plasma Exchange (TPE): To remove circulating complement factors and provide functional regulators.
  • Eculizumab: A monoclonal antibody that blocks terminal complement activation (C5 inhibitor).
  • Prophylactic Strategy: For a follow-up, more invasive surgery (Percutaneous Nephrolithotripsy), the team administered a prophylactic dose of eculizumab three days prior to the procedure to prevent a second "complement storm."

Datasets

Not discussed in the paper. This is a single-patient case report focusing on clinical observation and management rather than a large-scale data analysis or machine learning model.

Key Insights and Ideas

  • Surgery as a "Second Hit": The most significant insight is that even minimally invasive, "uneventful" endoscopic surgery can serve as a trigger for complement dysregulation in predisposed individuals. This expands the known clinical spectrum of aHUS triggers beyond major trauma or transplant.
  • The Sepsis Mimic: On postoperative day 1, the patient presented with fever, hypotension, and oliguria—classic signs of septic shock. The "aha moment" for the clinical team was recognizing that the rapid drop in hemoglobin and platelets, combined with negative cultures, pointed toward a primary hematological/complement issue rather than bacterial infection.
  • Successful Prophylaxis: The paper provides a proof-of-concept for using eculizumab as a preventative measure. By pre-treating the patient before her second surgery, the team successfully bypassed the complement activation that nearly killed her after the first procedure.

Key Results

  • Acute Phase: On postoperative day 1, the patient’s creatinine rose to 2.6 mg/dL, hemoglobin dropped from 14 g/dL to 8 g/dL, and platelets plummeted to a nadir of 23,000/µL.
  • Recovery: Following the initiation of eculizumab and plasma exchange, hemolytic markers and renal function normalized by postoperative day 10.
  • Follow-up Success: Two months later, the patient underwent a more invasive Percutaneous Nephrolithotripsy (PCNL). With prophylactic eculizumab, the procedure was completed with zero complications and stable renal function.

Limitations and Future Work

  • Single Case Observation: As a case report, the findings cannot be generalized to all urology patients without further study.
  • Genetic Testing: While the paper mentions family history (miscarriages, etc.) suggesting a genetic link, specific genetic mutation data for the patient (e.g., CFH, CFI, or CD46 mutations) were not detailed.
  • Future Directions: The authors suggest that further research is needed to explore the specific pathophysiological links between local renal trauma/hemodynamic stress and systemic complement activation. There is also a need for standardized protocols to identify "high-risk" patients who might benefit from complement screening before undergoing elective urological surgery.

Summary updated

Abstract

Renal failure, non-immune hemolytic anemia, and thrombocytopenia are the hallmarks of the uncommon but potentially fatal complement system-related illness known as atypical hemolytic uraemic syndrome (aHUS). We describe the case of a 46-year-old woman who underwent right retrograde intrarenal surgery (RIRS) for a 1.5 cm urinary stone in the renal pelvis and experienced septic shock on postoperative day 1 caused by aHUS. The patient received continuous venovenous hemodiafiltration (CVVHDF) for six days, eculizumab, a monoclonal antibody that blocks terminal complement activation, and three plasma exchanges with fresh frozen plasma, resulting in a progressive normalization of hemolytic parameters. Two months after the RIRS, the patient underwent percutaneous nephrolithotripsy to remove residual kidney stones. Three days before the surgery, she received a dose of eculizumab. The procedure went smoothly, and there were no postoperative complications. To the best of our knowledge, this is the report that mentions aHUS as a postoperative complication following endourology procedures. This report focuses on multidisciplinary diagnosis, treatment, and follow-up strategies for this unique complication in urology.
BibTeX
@inproceedings{creti2025rare,
  author = {Antonio Cretì and Francesco Pinto and Maria Chiara Sighinolfi and Bernardo Rocco and Domenico Salvatore Nigro and Mauro Ragonese},
  title = {{A Rare Case of Atypical Haemolytic Syndrome Following Right Retrograde Intrarenal Surgery (RIRS)}},
  booktitle = {Cureus},
  year = {2025},
  doi = {10.7759/cureus.86585},
}
Figure